Clinical trials: Corneal Disease
Refractive Error
Corneal Staining Associated With Daily Disposable Beauty Contact Lenses
Limbal ring contact lenses enhance the look of the eye by adding pigmentation in a ring pattern to the contact lens. The purpose of this investigation is to determine if corneal staining increase is dependent upon the lens…
- Trial name
- NCT01882465
- Testing
- etafilcon A, 2-HEMA, EGDMA Non-ionic, hefilcon A
- Where
- Hong Kong
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Cataract, Presbyopia
Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses
The purpose of this study is to characterize the safety and effectiveness of the ACRYSOF IQ ReSTOR +2.5 diopter (D) Multifocal Toric Intraocular Lens (IOL) in subjects at least 3 months and no more than 14 months after IOL…
- Conditions
- Cataract, Presbyopia, Corneal Astigmatism
- Trial name
- NCT02176343
- Testing
- AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Conjunctivitis
A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
To engage in a multi-center, prospective, masked clinical trial to investigate a non-invasive, rapid diagnostic test, the RPS Adeno Detector IV's ability to detect the presence of the adenovirus (ADV) antigen in cases of acute…
- Trial name
- NCT00921895
- Testing
- RPS Adeno Detector IV
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Rapid Pathogen Screening
Aphakia, Corneal Astigmatism
Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens
The purpose of this study is to evaluate the effectiveness and safety of the TFNT20 low cylinder power intraocular lens when implanted in the eye to replace the natural lens following cataract removal.
- Trial name
- NCT04542525
- Testing
- ACRYSOF IQ PanOptix Toric Trifocal IOL, Cataract surgery
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Cataract, Corneal Astigmatism
Evaluation of the Rotational Stability of the Tecnis Toric II IOL
This is a prospective, multicenter, single-arm, open-label clinical study of the commercially available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing unilateral or bilateral cataract surgery in up…
- Trial name
- STEELE (NCT04327518)
- Testing
- TECNIS® Toric II
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
- Trial name
- NCT00987727
- Testing
- carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi)
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Allergan
Neurotrophic Keratitis, Keratitis
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent…
- Conditions
- Neurotrophic Keratitis, Keratitis, Corneal Ulcer
- Trial name
- REPARO (NCT01756456)
- Testing
- rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle
- Where
- 34 sites in France, Germany and 4 more
- Volunteers
- 174 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye, Keratoconjunctivitis Sicca
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
- Trial name
- NCT05918406
- Testing
- Nasal Guide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Oyster Point Pharma, Inc.
Cataract, Corneal Astigmatism
ClarVista HARMONI Toric Trial With Intraoperative Exchange
The purpose of this study was to demonstrate the safety and effectiveness of the HARMONI® Modular Intraocular Lens System with a toric optic in subjects with pre-existing corneal astigmatism in need of cataract surgery.
- Conditions
- Cataract, Corneal Astigmatism, Aphakia
- Trial name
- NCT03054649
- Testing
- HARMONI® Modular Intraocular Lens System, Intraoperative optic exchange
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 44 people
- Sponsor
- ClarVista Medical
Corneal Edema, Corneal Endothelial Dysfunction
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.
- Trial name
- CLARA (NCT06041256)
- Testing
- AURN001, Corneal Endothelial Cells, Y27632
- Where
- 20 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Aurion Biotech
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Fuchs Endothelial Corneal Dystrophy
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD).
- Trial name
- PHANTOM (NCT05376176)
- Testing
- STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 86 people
- Sponsor
- Santen Inc.
Cataract, Corneal Astigmatism
Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens
This study will be a prospective, multicenter, bilateral, comparative, three-way masked (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites.
- Trial name
- BRAVO (NCT03949335)
- Testing
- IOL Model ZFR00V, IOL Model ZCB00
- Where
- 15 sites in United States
- Volunteers
- 272 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Keratoconus and Ectasia
Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia
The purpose of this research study is to evaluate the long tern safety and effectiveness of cross-linking in eyes with keratoconus and ectasia.
- Trial name
- NCT01398852
- Testing
- Riboflavin, VEGA UV-A Illumination System
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Topcon Medical Systems, Inc.
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Trial name
- INTREPID (NCT04520321)
- Testing
- TTHX1114(NM141)
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Trefoil Therapeutics, Inc.
Ectasia
Corneal Collagen Cross-Linking for Ectasia (CXL)
Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
- Trial name
- CXL (NCT00674661)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- Glaukos Corporation